Literature DB >> 26111946

Prevalence of cranial autonomic parasympathetic symptoms in chronic migraine: Usefulness of a new scale.

Nuria Riesco1, Angel I Pérez-Alvarez1, Laura Verano1, Carmen García-Cabo1, Juana Martínez-Ramos1, Pablo Sánchez-Lozano1, Eva Cernuda-Morollón1, Julio Pascual2.   

Abstract

BACKGROUND: Cranial autonomic symptoms (CAS) seem to appear in around half of migraine patients.
OBJECTIVE: Our aim was to analyse the prevalence and profile of CAS, mainly of cranial autonomic parasympathetic symptoms (CAPS), in a series of patients with chronic migraine (CM) according the new criteria for autonomic symptoms in the current IHS classification. PATIENTS AND METHODS: We recruited consecutive CM patients attending our headache clinic. Five CPAS were surveyed: lacrimation, conjunctival injection, eyelid oedema, ear fullness and nasal congestion. They were graded as 0 (absent), 1 (present and mild) and 2 (present and conspicuous); therefore the score in this CAPS scale ranges from 0 to 10 points. As a cranial autonomic sympathetic symptom (CSAS), we also asked about the presence of ptosis.
RESULTS: We interviewed 100 CM patients. Their mean age was 45 years (18-63 years); 93 were females. Eighteen had no CAPS, while 82 reported at least one CAPS. There were only six patients with scores higher than 5, the mean and median CAPS being 2.1 and 2, respectively. Prevalence of CAPS was lacrimation (49%), conjunctival injection (44%), eyelid oedema (39%), ear fullness (30%) and nasal congestion (20%). Ptosis was reported by 42.
CONCLUSION: These results, by using for the first time an easy quantitative scale, confirm that (mild) CAPS are not the exception but the rule in CM patients. The score in this CAPS scale could be of help as a further endpoint in clinical trials or to be correlated with potential biomarkers of parasympathetic activation in primary headaches. © International Headache Society 2015.

Entities:  

Keywords:  Chronic migraine; cranial autonomic symptoms; migraine

Mesh:

Year:  2015        PMID: 26111946     DOI: 10.1177/0333102415593087

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  16 in total

Review 1.  Headache and Autonomic Dysfunction: a Review.

Authors:  Courtney Iser; Karissa Arca
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-22       Impact factor: 6.030

Review 2.  Neuropeptides as a Marker for Chronic Headache.

Authors:  Nuria Riesco; Eva Cernuda-Morollón; Julio Pascual
Journal:  Curr Pain Headache Rep       Date:  2017-04

3.  The Function of the Autonomic Nervous System in Asian Patients With Chronic Migraine.

Authors:  Min Shi; Danqing Luo; Jun Guo; Dongdong Yang; Zhaoying Li; Huan Zhao
Journal:  Front Neurosci       Date:  2022-04-14       Impact factor: 4.677

4.  Autonomous control of cardiovascular reactivity in patients with episodic and chronic forms of migraine.

Authors:  Oleg V Mamontov; Laura Babayan; Alexander V Amelin; Rashid Giniatullin; Alexei A Kamshilin
Journal:  J Headache Pain       Date:  2016-05-11       Impact factor: 7.277

Review 5.  Allergic Rhinitis and Chronic Daily Headaches: Is There a Link?

Authors:  Anna Gryglas
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

6.  The cold pressor test in interictal migraine patients - different parasympathetic pupillary response indicates dysbalance of the cranial autonomic nervous system.

Authors:  Ozan E Eren; Ruth Ruscheweyh; Christoph Schankin; Florian Schöberl; Andreas Straube
Journal:  BMC Neurol       Date:  2018-04-16       Impact factor: 2.474

7.  Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia.

Authors:  Joan Crespi; Daniel Bratbak; David W Dodick; Manjit Matharu; Kent Are Jamtøy; Erling Tronvik
Journal:  Headache       Date:  2019-07-25       Impact factor: 5.887

8.  A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.

Authors:  Messoud Ashina; David Doležil; Jo H Bonner; Lifen Zhou; Jan Klatt; Hernan Picard; Daniel D Mikol
Journal:  Cephalalgia       Date:  2020-11-24       Impact factor: 6.292

9.  Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire.

Authors:  Mark J Burish; Stuart M Pearson; Robert E Shapiro; Wei Zhang; Larry I Schor
Journal:  Headache       Date:  2020-12-18       Impact factor: 5.887

10.  Low-frequency facial hemodynamic oscillations distinguish migraineurs from non-headache controls.

Authors:  Melissa M Cortez; Jeremy J Theriot; Natalie A Rea; Forrest E Gowen; K C Brennan
Journal:  Cephalalgia Rep       Date:  2019-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.